In an attempt to determine if galectin-3 can serve as a complementary biomarker to PSA to reduce false negative/positive results for PCa, we analyzed galectin-3 levels in the blood of metastatic PCa patients and compared it to the levels of galectin-3 in non-cancer subjects. The gene discussed is LGALS3; the disease is cancer.